fluorodeoxyglucose f18 has been researched along with crizotinib in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arango, ME; Binns, D; Bogatyreva, E; Christensen, JG; Cullinane, C; Dorow, DS; Hicks, RJ; Jackson, S; McArthur, GA; Solomon, B; Young, R | 1 |
| Bots, M; Cullinane, C; Martin, BP; Newbold, A | 1 |
| Fukushima, T; Gomi, D; Katou, A; Kobayashi, T; Koizumi, T; Mamiya, K; Oguchi, K; Sekiguchi, N; Tateishi, K | 1 |
| Dejust, S; El Farsaoui, K; Morland, D; Moubtakir, A; Prevost, A | 1 |
1 trial(s) available for fluorodeoxyglucose f18 and crizotinib
| Article | Year |
|---|---|
Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2017 |
3 other study(ies) available for fluorodeoxyglucose f18 and crizotinib
| Article | Year |
|---|---|
Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
Topics: Animals; Biomarkers; Cell Line, Tumor; Cell Proliferation; Crizotinib; Dideoxynucleosides; Disease Models, Animal; Fluorodeoxyglucose F18; Glucose; Glucose Transporter Type 1; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Transplantation; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Signal Transduction | 2011 |
Fluorodeoxyglucose-based positron emission tomography imaging to monitor drug responses in solid tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Crizotinib; Disease Models, Animal; Fluorodeoxyglucose F18; Humans; Mice; Positron-Emission Tomography; Pyrazoles; Pyridines; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2014 |
18F-FDG PET/CT Evaluation of Crizotinib and Lorlatinib Therapy in Metastatic ROS-1-Positive Non-Small Cell Lung Cancer.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Crizotinib; Fluorodeoxyglucose F18; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Pyrazoles; Radiopharmaceuticals | 2020 |